Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that its President and CEO, Jay R. Luly, Ph.D., will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2024, at 8:15 a.m. PT in San Francisco, CA.

The clinical-stage biotechnology company, which focuses on developing small molecule drugs for virology and immunology indications, will provide a live webcast of the presentation through the "Events and Presentations" section on the "Investors" page of their website. The webcast recording will remain available for a minimum of 30 days following the presentation.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108518953/en/

Media and Investors Contact:

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When is Enanta Pharmaceuticals (ENTA) presenting at the J.P. Morgan Healthcare Conference 2024?

Enanta Pharmaceuticals (ENTA) is presenting on Wednesday, January 15, 2024, at 8:15 a.m. PT in San Francisco, CA.

How can investors watch Enanta Pharmaceuticals' (ENTA) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available in the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com.

How long will Enanta Pharmaceuticals' (ENTA) J.P. Morgan presentation replay be available?

The webcast replay will be archived and available for at least 30 days following the presentation.

What is Enanta Pharmaceuticals' (ENTA) current business focus?

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on creating small molecule drugs for virology and immunology indications.